Biotechnology & Medical Research

Page 1

PuriCore Plc reaffirms FY 2014 outlook

3:00am EDT

PuriCore Plc:Says as expected, FY 2014 revenues and earnings will be lower than in the prior year as the business model in Supermarket Retail transitions and investments are made across the Group to support longer-term growth.Reported revenue of $54.75 mln, EPS of ($0.01) in FY 2013.FY 2014 revenue of $51.00 mln - Thomson Reuters I/B/E/S.

Miraca Holdings to acquire stake in Baylor Miraca Genetics Laboratories, LLC

2:15am EDT

Miraca Holdings Inc:To acquire 60 pct stake in Baylor Miraca Genetics Laboratories, LLC (BMGL) from Baylor College of Medicine (BCM), through Miraca USA, Inc., for about 15,400 mln yen in total in Feb. 2015.BMGL is a company engaged in provision of genetic testing service, which will be established by BCM in Jan. 2015.To hold 60 pct stake in BMGL after transaction.

Ina Research Inc lowers consolidated mid-year outlook for FY 2015

2:00am EDT

Ina Research Inc:Says the company lowered the consolidated mid-year outlook for revenue to 1,181 million yen from 1,460 million yen for FY ending March 2015.Sees a decrease of operating profit forecast to a loss of 52 million yen from 1 million yen.Sees a decrease of ordinary profit forecast to a loss of 62 million yen from a loss of 12 million yen.Sees a decrease of net profit forecast to a loss of 46 million yen from a loss of 7 million yen.Sees a decrease of earnings per share to a loss of 15.48 yen from a loss of 2.52 yen.Comments the increase in running cost and decreased income are the main reasons for the forecast.

Leaf Resources Ltd raises $1,707,000 in placement

Thursday, 30 Oct 2014 06:43pm EDT

Leaf Resources Ltd:Says that it has received acceptances for placement of 11,380,000 ordinary shares at $0.15, which will raise $1,707,000.Funds raised will be used to provide extra working capital for commercialisation of the company's GlycellTM process.

Affymetrix Inc raises FY 2014 guidance

Thursday, 30 Oct 2014 04:00pm EDT

Affymetrix Inc:Is raising FY 2014 guidance to total revenue of $345 million.FY 2014 adjusted EBITDA of about 17 pct of revenue.FY 2014 revenue of $342 mln, EBITDA of $44.3 mln - Thomson Reuters I/B/E/S.

Paratek Pharmaceuticals completes merger with Transcept Pharmaceuticals Inc

Thursday, 30 Oct 2014 01:31pm EDT

Paratek Pharmaceuticals Inc and Transcept Pharmaceuticals Inc:Says the two companies have completed their merger effective as of Oct. 30.The holders of shares of Paratek common stock outstanding immediately prior to the merger received 0.0675 shares of Transcept common stock in exchange for each share of Paratek common stock in the merger.The exchange ratio reflects the 12-1 reverse stock split.Also in connection with the merger, Transcept changed its name to Paratek Pharmaceuticals Inc.The combined company will commence trading as of Oct. 31 on The NASDAQ Global Market under the symbol PRTK.The combined company will operate under the leadership of Michael F. Bigham, Chairman and Chief Executive Officer.

Neurocrine Biosciences Inc receives breakthrough therapy designation for NBI-98854 in Tardive Dyskinesia

Thursday, 30 Oct 2014 07:30am EDT

Neurocrine Biosciences Inc:Says U.S. FDA has granted breakthrough therapy designation for its vesicular monoamine transporter 2 inhibitor, NBI-98854, in tardive dyskinesia.Breakthrough therapy designation is granted for drug that is intended to treat serious or life-threatening disease or condition and preliminary clinical evidence indicates that drug may demonstrate substantial improvement on clinically significant endpoints over available therapies.Breakthrough designation also allows intensive discussions with FDA which are intended to expedite development and review process of eligible drugs.Breakthrough Therapy Designation was granted, in part, based on results of Phase IIb Kinect studies of NBI-98854 in about 220 patients with tardive dyskinesia.

Acorda Therapeutics Inc raises FY 2014 AMPYRA net revenue outlook

Thursday, 30 Oct 2014 06:02am EDT

Acorda Therapeutics Inc:Raised FY 2014 guidance for AMPYRA Net Revenue from $328-$335 mln to $345-$350 mln.

Quintiles Transnational Holdings Inc raises FY 2014 EPS guidance

Thursday, 30 Oct 2014 06:00am EDT

Quintiles Transnational Holdings Inc:Raised diluted adjusted EPS to a range $2.61-$2.68 per share and diluted GAAP EPS between $2.61-$2.68 per share.FY 2014 EPS of $2.64 - Thomson Reuters I/B/E/S.

Chiome Bioscience Inc amends consolidated full-year outlook for FY 2014

Thursday, 30 Oct 2014 03:00am EDT

Chiome Bioscience Inc:Says the company amended the consolidated full-year outlook for the FY ending Dec. 2014.Revenue forecast decreased to 277 million yen from 342 million yen.Operating profit forecast increased to a loss of 907 million yen from a loss of 1,043 million yen.Ordinary profit forecast increased to a loss of 907 million yen from a loss of 1,041 million yen.Net profit forecast increased to a loss of 891 million yen from a loss of 1,043 million yen.Earnings per share forecast increased to a loss of 44.04 yen from a loss of 54.56 yen.Comments that decreased jointly research income and adjustment of research and development activity are the main reasons for the forecast.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.